Timing of Transplant for Multiple Myeloma
|
|
- Elfrieda Lucas
- 5 years ago
- Views:
Transcription
1 Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing
2 Initial Approach to Treatment of Myeloma Nontransplantation candidate (based on age, performance score, and comorbidities) Induction treatment Maintenance Transplantation candidate Induction treatment (nonalkylator-based induction x 4-6 cycles) Stem cell harvest Stem cell transplantation Consolidation therapy? Maintenance
3 VGPR/CR Postinduction and Post-ASCT in Phase III Trials of Novel Therapies vs VAD CR/VGPR 100% 50% 0% P = % CR/VGPR VGPR CR/nCR Doublet P = % P = % 37.7% P < % 19.3% P < % 37% P =.03 40% 22.9% 18.8% 21% 35.0% 18% 32% 31% 12.6% 15.1% 34% 30% 16% 15% 14.8% 8.7% 18.4% 15% 3% 14% 6.4% 2% 12% 11% 5% TD VAD TD VAD VD VAD VD VAD TAD VAD TAD VAD PAD VAD PAD VAD Pre-HDT Post-HDT Pre-HDT Post-HDT Pre-HDT Post-HDT Pre-HDT Post-HDT Macro IFM HOVON 50 HOVON 65 54% 44% P < % 73.7% P <.001 P < % 66% 61% 62.3% 31% 36% Triplet P < % 55.1% 27.2% 27.5% 40.9% 17.1% 16% 10.4% P = % CTD CVAD CTD CVAD Pre-HDT Post-HDT MRC IX 35% 31% 28% 17% 11% P < % 32% 55% 64% 23% TD 41% 60% 100% 67% CR/nCR 43% CR/nCR 33% VTD TD VTD TD CyBorD RVD Pre-HDT Post-HDT GIMEMA Macro M, et al. Blood. 2006;108: Harousseau JL, et al. J Clin Oncol. 2010;28: Lokhorst HM, et al. Blood. 2010;115: Sonneveld P, et al. IMW Abstract 40. Cavo M, et al. Lancet. 2010;376: Reeder CB, et al. Blood. 2009;114: abstract 616. Richardson PG, et al. Blood. 2009;114: abstract Kumar SK, et al. Leukemia. 2010;24:
4 Chemotherapy vs. Transplant Not all randomized studies, however, have shown a benefit San-Miguel, JF & Mateos, M-V. Hematology 2009, ASH Education Book.
5 Autologous SCT vs. CCT Progression-free survival is improved by autologous stem-cell transplantation vs. conventional chemotherapy Koreth, J et al. Biol Blood Marrow Transplant. 13: 183, 2007.
6 Overall Survival Impact Survival benefit is less impressive in this metaanalysis Koreth, J et al. Biol Blood Marrow Transplant. 13: 183, 2007.
7 Single or Double ASCT? Double autologous stem cell transplantation provides advantages over single transplantation Attal, M et al. N Engl J Med. 349: 2495, 2003.
8 Subgroup Benefits Benefits were especially notable in patients who did not achieve a CR or VGPR after their first autologous stem cell transplant Attal, M et al. N Engl J Med. 349: 2495, 2003.
9 Consolidation Therapy Post-transplant consolidation with 4 cycles of VTD CR 15% 49% Molecular CR 3% 18% Tumor burden reduced 4.14 logs Ladetto, M et al. J Clin Oncol. 28: 2077, 2010.
10 PFS (%) OS (%) PETHEMA: Long-term Follow-up P = P = Yrs From Transplantation Yrs From Transplantation CR (n = 84) ncr (n = 66) + VGPR (n = 54) + PR (n = 114) SD (n = 12) + PD (n = 14) Functional cure? Martinez-Lopez J, et al. Blood. 2011;118:
11 MRD and outcomes DNA(VDJ: sequenta method) 2013ASH abstract # 1848 Martinez-Lopez et al
12 Lenalidomide Maintenance : CALGB TTP 46 mos. with len vs. 27 mos. for placebo 35 deaths on len arm vs. 53 on placebo arm McCarthy, P et al. N Engl J Med. 366:1770, 2012.
13 Phase 3 GIMEMA: VTD vs TD Bortezomib/Thalidomide/Dexamethasone vs Thalidomide/Dexamethasone Untreated multiple myeloma in pts 65 yrs of age (N = 474) Bort Thal Dex 1:1 Thal Dex CTX Melphalan + ASCT Bort Thal Dex 1:1 Thal Dex Dex Induction: Three 21-day cycles; bortezomib 1.3 mg/m 2 on Days 1, 4, 8, 11; thalidomide mg/day on Days 1-63; dexamethasone 320 mg/cycle Consolidation: Two 35-day cycles; bortezomib 1.3 mg/m 2 on Days 1, 8, 15, 22; thalidomide 100 mg/day on Days 1-70; dexamethasone 320 mg/cycle Cavo M, et al. Lancet. 2010;376:2075. Cavo M, et al. Blood. 2012;120:9-19.
14 GIMEMA: VTD vs TD Results Response to Induction,* % Bort/Thal/Dex (n = 236) OS at 30 mos was not significantly different Thal/Dex (n = 238) P Value CR 19 5 <.0001 CR + ncr <.0001 VGPR <.0001 Response to Protocol,* % Bort/Thal/Dex Thal/Dex P Value CR CR + ncr <.0001 VGPR <.0001 PR yr PFS PFS remained superior with VTD when analyzed by age, ISS stage, LDH level, albumin level, del(13q), t(4;14), and del(17p) *Centrally assessed. Cavo M, et al. Lancet. 2010;376:
15 Probability of Survival Without Progression GIMEMA: VTD vs TD PFS % relative reduction of risk of progression or death in VTD arm VTD HR: 0.63 (CI: ; P =.0061) Probability at 3 yrs, % P =.0057 VTD 68 TD 56 TD 0 Cavo M, et al. Lancet. 2010;376: Mos
16 Early vs. Salvage Transplant Untreated, symptomatic patients < 56 (N = 202) Successf ul PBSC collection (N = 185) Early HDT 1 Induction VAMP x 3-4 cycles Preparatory lomustine, VP-16, cyclophosphamide, melphalan at 140 mg/m 2 + TBI Then auto-pbsct (n = 91) Late HDT 1 Monthly VMCP For patients PR continue to plateau Transplant as per above if progression, resistance after 6 cycles, or in relapse (n = 94) Fermand, JP et al. Blood 92: 3131, 1998.
17 Consort Chart Fermand, JP et al. Blood 92: 3131, 1998.
18 Overall Survival 80% 73% 78% 66% 71% 61% No difference in overall survival at median follow-up of 58 months Fermand, JP et al. Blood 92: 3131, 1998.
19 Quality of Life Longer time without symptoms, treatment, and treatment toxicity (TwiSTT) 27.8 months for early HDT, vs months for salvage HDT Fermand, JP et al. Blood 92: 3131, 1998.
20 Data After Longer Follow-up Comparable OS (A; 47.8 vs mos.) and EFS (B; 25.3 vs mos.) with median follow-up of 120 months Fermand, J-P et al. J Clin Oncol. 23: 9227, 2005.
21 Improved Quality of Life Maintained longer time without symptoms, treatment, and treatment toxicity (TwiSTT) Fermand, J-P et al. J Clin Oncol. 23: 9227, 2005.
22 Early Harvest and Late Transplant Stem cells collected within 6 mos. of diagnosis Received VAD Transplant at progression Median 38 mos. Gertz, MA et al. Bone Marrow Transplant. 23: 221, 1999.
23 Concluded Late Transplant Feasible Median survival 58.5 months Underlying biology of the disease has a greater impact on survival than the timing of transplant Gertz, MA et al. Bone Marrow Transplant. 23: 221, 1999.
24 E4A03 Study Design Lenalidomide R E G I S T R A T I O N 25 mg po days High dose Dex 40 mg days 1-4, 9-12, x 4 cycles 445 patients Lenalidomide 25 mg po days Low dose Dex 40 mg days 1, 8, 15, 22 x 4 cycles CR/PR/ Stable Less than PR SCT possible as early as 4 months Thal/dex x 4 cycles Rajkumar, SV et al. Lancet Oncol. 11: 29, 2010.
25 RD vs. Rd 96% 87% Stopped early; recommendatio n of IDMC; median followup of 12.5 months 87% 75% More is not necessar ily better in the novel agent era Rajkumar, SV et al. Lancet Oncol. 11: 29, 2010.
26 With Longer Follow-up Rajkumar, SV et al. Lancet Oncol. 11: 29, 2010.
27 Off after 4 No SCT Off after 4 + SCT Continued past 4 cycles Landmark Analysis 90 patients went off LD or Ld after 4 cycles for SCT OS 92% at 3 years 248 patients continued on therapy past the initial 4 cycles 79% 3-year overall survival PFS at 3 years 46% for RD vs. 50% for Rd Rajkumar, SV et al. Lancet Oncol. 11: 29, 2010.
28 Landmark Analysis 431 patients alive at 4 cycles Off therapy at 4 cycles n=183 Primary therapy beyond 4 cycles n=248 no transplant N=93 (median age 68) Transplant n=90 (median age 57) Ld n=140 (median age 66) LD n=108 (median age 65)
29 Outcomes in Younger Patients (<65) Progression Free Survival Overall Survival
30 Outcomes in Older Patients ( 70) Progression Free Survival Overall Survival
31 Case Control Study 290 patients treated with an IMiD-based induction regimen prior to transplant 123 got TD, 167 got LD Late transplant: occurred after 12 months 42 had gotten SCT; median 44.5 mos. Early transplant: within 2 months of harvest, 12 months of diagnosis Median 5.3 mos. to SCT Kumar, SK et al. Cancer 118: 1585, 2012.
32 Outcomes Four year overall survival was identical in the two groups (73%) TD 68% vs. 64% LD 82% vs. 86% Time to progression after transplant similar 20 mos. (early) vs. 16 mos. (late) Kumar, SK et al. Cancer 118: 1585, 2012.
33 IFM/DFCI 2009 Study Randomize RVDx3 Induction RVDx3 CY (3 g/m 2 ) MOBILIZATION Goal: 5 x 10 6 cells/kg Collection CY (3 g/m 2 ) MOBILIZATION Goal: 5 x 10 6 cells/kg Melphalan 200mg/m 2 + ASCT Consolidation RVD x 5 RVD x 2 Maintenance Lenalidomide 18 mos Lenalidomide 18 mos SCT at relapse
34 Is Achieving CR the Key? GEM2000 trial 1,075 pts enrolled 632 responseassessable Uniform induction VBMCP followed by VBAD Lahuerta, JJ et al. J Clin Oncol. 26: 5775, 2008.
35 Value of CR Post-transplant After induction, patients went on to single or tandem high dose chemotherapy with autologous stem cell rescue Lahuerta, JJ et al. J Clin Oncol. 26: 5775, 2008.
36 Value of CR in IFM Studies IFM and trials VAD, then tandem ASCT Best post-asct data available for 802 pts Harousseau, J-L et al. J Clin Oncol. 27: 5720, 2009.
37 Value of CR in Asia Korean Multiple Myeloma Working Party study of 197 chemosensitive patients who received a single SCT CR prior to transplant (upper panel) and after transplant (lower panel) predicted a better outcome Kim, JS et al. Biol Blood Marrow Transplant. 15: 463, 2009.
38 Role of CR in Total Therapy 3 Barlogie, B et al. Br J Haematol. 138: 176, 2007.
39 Achieving and Maintaining CR Sustaining CR within a 3-year landmark from treatment initiation was associated with a highly superior survival (P <0.0001) Achieving and losing CR worse than no CR Barlogie, B et al. Cancer 113: 355, 2008.
40 Allogeneic Transplantation Only curative procedure in MM but recommended only in context of a clinical trial Associated with high TRM and morbidity Superior outcomes with use of novel agents in standard-risk patients Lack of allogeneic transplantation benefit in high-risk patients Several RIC regimens developed to avoid high TRM; offers short-term decrease in TRM, but higher rate of relapse Only 2 of 6 randomized trials of double ASCT vs ASCT with allogeneic RIC showed superior PFS and OS for allogeneic regimen Most recent data: tandem ASCT vs ASCT/allogeneic RIC from matched siblings; no benefit seen with early allogeneic RIC (relatively short follow-up) Lonial S, et al. J Natl Compr Canc Netw. 2013;11: Lokhorst H, et al. J Clin Oncol. 2010;28: Krishnan A, et al. Lancet Oncol. 2011;12: Stadtmauer EA, et al. Blood. 2010;116: Abstract 526. Lokhorst H, et al. Blood. 2012;119: Moreau P. Blood. 2012;119:
41 Long survival after AUTO/ALLO transplant Hospital Maisonneuve-Rosemont Montreal 93 pts: tandem Auto/mini-Allo PFS 44% at 10 years; OS 64% GVHD: grade 2-4 acute 9%; extensive chronic 85% ASH abstract #3353 Ahmad et al
42 M. D. Anderson Data Retrospective analysis of 758 patients with newly-diagnosed myeloma Received dex-based induction -/+ highdose therapy (+ in 395) within 1 year Groups were comparable in b 2 m, SCr, ISS stage Wang, M et al. Bone Marrow Transpl. 45: 498, 2010.
43 SCT in CR High dose therapy did not improve outcomes for patients already in CR Wang, M et al. Bone Marrow Transpl. 45: 498, 2010.
44 Other Considerations Access to novel agents SCT may best achieve cytoreduction/cr if novel agent access is limited Cost of chemotherapy vs. transplant SCT is a cost-effective way to achieve rapid cytoreduction vs. long-term novel drugs Allows novel agents to be reserved for the time of relapse, thereby saving healthcare resources
45 Conclusions Randomized trials are needed in the novel agent era comparing the effectiveness of early vs. delayed transplant Available (albeit limited) data do not suggest that patient outcomes are compromised by reserving transplant until first relapse Possibility remains that relapse after novel agent induction/consolidation/maintenance may be less sensitive to melphalan-based approaches
Terapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationHow to treat a newly diagnosed young patient with multiple myeloma
How to treat a newly diagnosed young patient with multiple myeloma J.F. San Miguel University of Salamanca, Spain Department of Haematology University of Salamanca Cancer Research Centre Disclosures for
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationStem Cell Transplantation in Multiple Myeloma
Stem Cell Transplantation in Multiple Myeloma Michel Attal, Philippe Moreau, Herve Avet-Loiseau, and Jean-Luc Harousseau Service d Hématologie, Hôpital Purpan, Toulouse, France Multiple myeloma (MM) is
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationIncorporating Novel Agents in the Transplant Setting
Optimizing Therapeutic Sequencing in Myeloma Can Induction - Autologous SCT -Consolidation-Maintenance Lead to Improved Outcome? Paul G. Richardson, MD Jerome Lipper Multiple Myeloma Center Dana-Farber
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationPosttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma Donna E. Reece 1 1 Princess Margaret Hospital, Toronto, ON One of the major
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationTratamiento actual del mieloma multiple y papel del trasplante en la era de las nuevas drogas
Tratamiento actual del mieloma multiple y papel del trasplante en la era de las nuevas drogas IBiS INSTITUTODEBIOMEDICINADESEVILLA José A Pérez-Simón UGC Hematologia Hospital Universitario Virgen del Rocío
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationNew myeloma drugs improve response and extend survival
The JCSO Interview New myeloma drugs improve response and extend survival David H Henry, MD, a interviews Kenneth C Anderson, MD b a Department of Medicine, University of Pennsylvania Perelman School of
More informationNovel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationAUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA. Binod Dhakal MD, MS Jeanie Esselmann, RN
AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA Binod Dhakal MD, MS Jeanie Esselmann, RN BACKGROUND OF MULTIPLE MYELOMA Accounts for 1% of all cancers, and 10% of hematological malignancies The American
More informationASBMT. Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Biol Blood Marrow Transplant 19 (2013) 445e449 Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma Emilie Lemieux 1,y, Cyrille Hulin 2,y, Denis Caillot 3, Stéphanie Tardy
More informationMyeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco
Myeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco Survival in Myeloma IFM DFCI; 2015 2011-14 2001-10 1961-70 1991-2000 Kumar S.
More informationAdvances in therapy of multiple myeloma Joan Bladé and Laura Rosiñol
Advances in therapy of multiple myeloma Joan Bladé and Laura Rosiñol Hematology and Oncology Institute, Hematology Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain Correspondence
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More information